Microcredencial universitaria en CIVIS – Design and development of RNA therapies for human diseases (Ed. 1)
PRESENTACIÓN
RNA therapies for both rare and common diseases (cardiovascular and neurodegenerative diseases, cancer, etc.) have witnessed a powerful acceleration with the success of COVID-19 mRNA vaccines and also with the approval of eleven oligonucleotide-based drugs in recent years. Therefore, these nucleic acids-based treatments are gaining increasing social, political, and economic interest.
OBJETIVO
Train students in all relevant aspects of the design and preclinical and clinical testing of RNA therapies and learning how to effectively and adequately communicate among relevant stakeholders.
PROGRAMA:
1) RNA therapies and their Delivery
- Introduction: Types of RNA and their function
- Nobel Prize 2023: mRNA’s Journey from Vaccines to Therapeutics
- Translational readthrough: nonsense suppressor tRNAs
- Antisense oligonucleotides for neurodegenerative disease
- Exon skipping antisense oligonucleotides
- Silencing strategies in cancer and regenerative medicine
- LncRNAs
- Delivery strategies for RNA drugs
2) Translating RNA therapies to the clinics
- In vitro and in vivo models for preclinical testing
- Safety and toxicology, regulatory issues
3) Communicating RNA Therapies to Stakeholders
- Science dissemination and bioethics
- Moving from academia to industry
- Patients’ voice
DÍAS, HORARIO Y LUGAR DE CELEBRACIÓN:
- Días: Monday to Friday, 16th-19th and 22nd -26th June 2026
- Horario: from 16.00 to 19.00 (CET)
- Lugar de celebración: online